Case Study: Bridging the Gap: Navigating the Translation to Clinic in TCR-T Development

Time: 1:30 pm
day: Conference Day One


  • Key strategies and considerations for translating TCR-T therapies from preclinical development to clinical applications
  • The FIH study of an HLA-class II restricted HPV18 E7 specific TCR cloned from a long-term surviving cervical cancer patient
  • Beside affinity, what did we learn from TCR-T development?
  • Deciding on a preclinical model and data package